On October 2, McKesson rose 4.52% in regular trading, trading at $891.77/share, with turnover of approximately $349 million. The gain comes amid broad strength across the Health Care Distributors sector, with peers Cardinal Health up 3.03% and Cencora up 2.33%.

On the news front, Aetna, a subsidiary of CVS Health, announced an expansion of its prior authorization bundles across all cancer types for eligible Medicaid members starting September 1, with plans to extend bundled approvals across all lines of business by 2027. The initiative, which saw nearly 25% of eligible members receive a bundled prior authorization in its initial rollout, is expected to benefit McKesson's Prescription Technology Solutions and oncology-focused segments.

The positive sentiment is further supported by McKesson's pending $2.25 billion acquisition of Precision Medicine Group, which will be integrated into its Oncology and Multispecialty business segment, expanding clinical research and drug commercialization capabilities. Multiple analysts have recently raised price targets, with BofA Securities at $1,050, Barclays at $1,000, and Citigroup at $1,000, all maintaining buy-equivalent ratings. The consensus mean target stands near $988.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)